Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe active rheumatoid arthritis.

Trial Profile

A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe active rheumatoid arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMBITION; AMBITION-LTE
  • Sponsors Roche
  • Most Recent Events

    • 24 Oct 2018 Results assessing the effect of stable concomitant GC treatment on efficacy of Methotrexate or Tocilizumab or Adalimumab monotherapy in AMBITION, ACT-RAY, ADACTA and FUNCTION trials, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 16 Jun 2018 Results comparing pain and HAQ-DI from RA-BEGIN, PREMIER, ORAL-START, AMBITION and FUNCTION studies were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of pooled post-hoc analysis from four studies (AMBITION, ACT-RAY, ADACTA and FUNCTION) presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top